ClinicalTrials.gov
ClinicalTrials.gov Menu

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) (ECOSPOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02437487
Recruitment Status : Completed
First Posted : May 7, 2015
Results First Posted : July 26, 2018
Last Update Posted : July 26, 2018
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
Seres Therapeutics, Inc.

Brief Summary:
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.

Condition or disease Intervention/treatment Phase
Clostridium Difficile Drug: SER-109 Drug: Placebo Phase 2

Detailed Description:

ECOSPOR is a Phase 2, multicenter, randomized, double blind, placebo controlled clinical study with 2 treatment arms (SER-109 or placebo). Patients who have diarrhea and a positive C. difficile test result on a stool sample, and who have responded to standard of care antibiotic treatment will receive study drug on Day 1.

Those patients who experience a recurrence of CDI up to 8 weeks after SER 109 or placebo treatment will be offered an opportunity to enroll in an open label SER 109 extension study (Study SERES 005).


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 89 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection
Study Start Date : May 2015
Actual Primary Completion Date : July 2016
Actual Study Completion Date : October 2016

Arm Intervention/treatment
Experimental: SER-109
SER 109 (1 × 108 SporQs)
Drug: SER-109
SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
Other Name: Purified Eubacterial Spores, Encapsulated

Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.




Primary Outcome Measures :
  1. Number of Subjects With CDI Recurrence [ Time Frame: 8 weeks after treatment. ]

Secondary Outcome Measures :
  1. Time to Recurrence of CDI [ Time Frame: Recurrence of CDI up to 24 weeks after treatment. ]
    Kaplan-Meier estimate of median number of days to recurrence

  2. Number of Subjects With CDI Recurrence [ Time Frame: 4 Weeks ]
  3. Number of Subjects With CDI Recurrence [ Time Frame: 12 Weeks ]
  4. Number of Subjects With CDI Recurrence [ Time Frame: 24 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent, indicating that the patient understands the purpose of and procedures required for the study. Patients who are unable to provide informed consent will not be included in the study.
  2. Male or female patients ≥ 18 years.
  3. ≥ 3 episodes of CDI within the previous 9 months, inclusive of the current episode with documentation of ≥ 2 episodes.

Exclusion Criteria:

  1. Female patients who are pregnant, breastfeeding, lactating, or planning to become pregnant during the study.
  2. Known or suspected toxic megacolon and/or known small bowel ileus.
  3. Active irritable bowel syndrome with diarrhea within the previous 12 months.
  4. Major gastrointestinal surgery (eg, significant bowel resection or diversion) within 3 months before enrollment (this does not include appendectomy or cholecystectomy) or any history of total colectomy or bariatric surgery.
  5. History of inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic colitis) with diarrhea believed to be caused by active inflammatory bowel disease in the past 24 months.
  6. Admitted to or expected to be admitted to an acute care facility or intensive care unit for medical reasons (not just boarding). Patients discharged from an acute care facility before Day 1 or residing in nursing homes or rehabilitation facilities may be enrolled.
  7. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy (patients on maintenance chemotherapy may only be enrolled after consultation with medical monitor).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02437487


  Show 30 Study Locations
Sponsors and Collaborators
Seres Therapeutics, Inc.
Syneos Health
Investigators
Study Director: Michele Trucksis, Phd, MD Seres Therapeutics

Responsible Party: Seres Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02437487     History of Changes
Other Study ID Numbers: SERES-004
First Posted: May 7, 2015    Key Record Dates
Results First Posted: July 26, 2018
Last Update Posted: July 26, 2018
Last Verified: June 2018